ArticleCardiology research and practice2011
Review of cardiotoxicity in pediatric cancer patients: during and after therapy.
Article in Cardiology research and practice, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Pregnancy associated cardiomyopathy in 2 cancer survivors with history of anthracycline use.American heart journal plus : cardiology research and practice · 2025Article
- The Potential Role of GLP1-RAs Against Anticancer-Drug Cardiotoxicity: A Scoping Review.Journal of clinical medicine · 2025Review
- Article
- Institutional experience of using active breathing control for paediatric and teenage patients receiving thoraco-abdominal radiotherapy.Clinical and translational radiation oncology · 2023Article
- Cardio-Oncology in Childhood: State of the Art.Current oncology reports · 2022Review
- Review
- Review
- Genetic factors in treatment-related cardiovascular complications in survivors of childhood acute lymphoblastic leukemia.Pharmacogenomics · 2021Article
- Pulmonary Hypertension as a Complication of Pediatric Cancer.Global pediatric health · 2021Review
- Cardiotoxicity: A Major Setback in Childhood Leukemia Treatment.Disease markers · 2021Review
- Cardiovascular diseases in survivors of childhood cancer.Cancer metastasis reviews · 2020Review
- Use of speckle tracking in the evaluation of late subclinical myocardial damage in survivors of childhood acute leukaemia.The international journal of cardiovascular imaging · 2018Article
- Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.BMC cancer · 2018Article
- Evaluation of the phytochemical composition and protective activities of methanolic extracts ofFood & nutrition research · 2017Article
- Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation.British journal of cancer · 2016Article
- Pregnancy-associated cardiomyopathy in survivors of childhood cancer.Journal of cancer survivorship : research and practice · 2016Article
- The differential effects of green tea on dose-dependent doxorubicin toxicity.Food & nutrition research · 2015Article
- Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2014Article
- Heart repolarization changes after anthracycline therapy in the children with cancer.Iranian journal of pediatric hematology and oncology · 2014Article
- Why Healthcare Providers Should Focus on the Fertility of AYA Cancer Survivors: It's Not Too Late!Frontiers in oncology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the improvement in survival from childhood cancer, late effects of therapy are becoming more apparent. Cardiac disease, one of these late effects, has a significant impact on the life of survivors of childhood cancers. Most survivors are followed by primary care doctors and adult subspecialists after they have graduated from pediatric centers. Since much of the cardiac toxicity of therapy occurs years off of therapy, it is important for these physicians to be aware of how to monitor survivors for the development of cardiac toxicities. In this paper we will discuss the incidence of cardiac disease during treatment and in survivors, what treatment modalities contribute to its development and modalities utilized to screen for cardiac disease. Recommendations for posttherapy monitoring will be emphasized.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.